Published: Apr 12, 2021
TARRYTOWN, N.Y., April 12, 2021 /PRNewswire/
REGEN-COV rapidly protected household contacts from exposure to SARS-CoV-2 at home, with 72% protection against symptomatic infections in the first week, and 93% in subsequent weeks
Among individuals who developed symptomatic infections, REGEN-COV recipients cleared the virus faster and had much shorter symptom duration
Regeneron will share data with U.S. FDA and request EUA expansion to include COVID prevention for appropriate populations, using a 1,200 mg subcutaneous dose
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced positive results from a Phase 3 trial (2069A) assessing the ability of REGEN-COV™ (casirivimab with imdevimab) to reduce the risk and burden of COVID-19 infection among household contacts of SARS-CoV-2 infected individuals. The trial, which was jointly run with the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (
Laurel Wamsley
Laurel Wamsley is a reporter for NPR s News Desk. She reports breaking news for NPR s digital coverage, newscasts, and news magazines, as well as occasional features. She was also the lead reporter for NPR s coverage of the 2019 Women s World Cup in France.
Wamsley got her start at NPR as an intern for
Weekend Edition Saturday in January 2007 and stayed on as a production assistant for NPR s flagship news programs, before joining the Washington Desk for the 2008 election.
She then left NPR, doing freelance writing and editing in Austin, Texas, and then working in various marketing roles for technology companies in Austin and Chicago.
Regeneron Pharmaceuticals (NASDAQ: REGN) announced Monday that it is prepared to ask the Food and Drug Administration for approval to use its Covid-19 antibody therapy as a preventative treatment.
TTP399 SimpliciT-1 Study Results to be presented at a scientific symposium in celebration of the 100th anniversary of the discovery of insulin streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
Psilocybin Mushrooms Use For Mental Health Research By The Recover forextv.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from forextv.com Daily Mail and Mail on Sunday newspapers.